www.OrthoPediatrics.com Disclaimer Forward-Looking Statements 2026 Investor Presentation All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "ma ...

Core Insights - OrthoPediatrics reported revenue of $61.61 million for the quarter ended December 2025, marking a year-over-year increase of 17% and exceeding the Zacks Consensus Estimate by 4.05% [1] - The company’s EPS for the same period was -$0.26, an improvement from -$0.29 a year ago, with a surprise of 29.73% compared to the consensus estimate of -$0.37 [1] Revenue Performance - Product sales in the Trauma and deformity category reached $42.64 million, slightly below the estimated $43.45 million, but still reflecting a year-over-year increase of 17.1% [4] - Sales in the Sports medicine/other category were reported at $1.37 million, significantly surpassing the average estimate of $0.68 million, representing a remarkable year-over-year growth of 118.5% [4] - Scoliosis product sales amounted to $17.6 million, exceeding the estimated $15.17 million, with a year-over-year increase of 12.6% [4] Stock Performance - Over the past month, OrthoPediatrics shares have returned -3.5%, contrasting with the Zacks S&P 500 composite's increase of +0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

OrthoPediatrics (NasdaqGM:KIDS) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsCaitlin Cronin - Director of MedTech Equity ResearchDavid Bailey - President and CEOFred Hite - COO and CFOMathew Blackman - Managing Director of Medical Technology Equity ResearchTrip Taylor - Investor RelationsConference Call ParticipantsBenjamin Haynor - Senior Research AnalystMatthew O'Brien - Managing Director and Senior Research AnalystMike Matson - Senior AnalystRavi Misra - VP and Associate Analys ...

OrthoPediatrics (NasdaqGM:KIDS) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsCaitlin Cronin - Director of MedTech Equity ResearchDavid Bailey - President and CEOFred Hite - COO and CFOMathew Blackman - Managing Director of Medical Technology Equity ResearchTrip Taylor - Investor RelationsConference Call ParticipantsBenjamin Haynor - Senior Research AnalystMatthew O'Brien - Managing Director and Senior Research AnalystMike Matson - Senior AnalystRavi Misra - VP and Associate Analys ...

OrthoPediatrics (NasdaqGM:KIDS) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker7Good afternoon, welcome to OrthoPediatrics Corp.'s fourth quarter 2025 conference call. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Trip Taylor, Investor Relations, for a few introductory comments.Speaker9Thank you ...

Record full year 2025 revenue of $236.3 million increased 15% compared to prior yearOperating Cash flow improvement of $22 million in full year 2025Generated $10 million of free cash flow in the fourth quarter, the first quarter of positive free cash flow in Company history WARSAW, Ind., Feb. 26, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial resu ...

Core Viewpoint - OrthoPediatrics Corp. is set to release its fourth quarter and full year 2025 financial results on February 26, 2026, and will host a conference call to discuss these results [1]. Company Overview - OrthoPediatrics Corp. was founded in 2006 and focuses exclusively on pediatric orthopedics, offering a comprehensive range of products to improve the lives of children with orthopedic conditions [3]. - The company markets over 85 products across three major categories: trauma and deformity, scoliosis, and sports medicine/other procedures [3]. - OrthoPediatrics has a global sales organization dedicated to pediatric orthopedics, distributing products in the United States and over 75 countries worldwide [3].

Core Insights - iotaMotion has received FDA 510(k) clearance for its iotaSOFT Insertion System, now approved for use in pediatric patients aged four years and older, enhancing access to robotic-assisted cochlear implantation for school-aged children [1][2] Company Overview - OrthoPediatrics Corp. focuses exclusively on pediatric orthopedics and has developed a comprehensive product offering to improve the lives of children with orthopedic conditions, marketing over 85 products across three major categories: trauma and deformity, scoliosis, and sports medicine [4] - The company aims to expand its impact in pediatric care by leveraging advanced technologies like the iotaSOFT system, which aligns with its mission to address unmet pediatric needs [3] Partnership and Technology - The partnership with iotaMotion aims to enhance cochlear implant surgery through the iotaSOFT system, which is the first FDA-authorized open platform robotic-assisted technology designed to reduce surgical variability [2] - Cincinnati Children's Hospital has become the first dedicated pediatric center to adopt the iotaSOFT Insertion System, joining over 35 leading cochlear implant centers in the U.S. [3] Industry Impact - The introduction of robotic-assisted cochlear implantation is seen as a significant advancement in the cochlear implant program, reflecting a commitment to integrating innovations that benefit patient care [4]

Core Viewpoint - OrthoPediatrics (KIDS) experienced a significant stock price increase of 9.8% to close at $20.11, driven by strong trading volume and positive investor sentiment following the announcement of preliminary financial highlights for 2025 [1][2]. Financial Performance - The company reported record preliminary unaudited net revenue of $236.1 million for the full year 2025, reflecting a year-over-year growth of 15% [2]. - For the upcoming quarterly report, OrthoPediatrics is expected to report a loss of $0.29 per share, which is consistent with the same quarter from the previous year. Revenue is anticipated to be $59.21 million, marking a 12.4% increase from the year-ago quarter [3]. Earnings Estimates and Stock Movement - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating a lack of upward revisions in earnings estimates, which typically correlates with stock price movements [4]. - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook, while OPKO Health, another company in the same industry, has a Zacks Rank of 2 (Buy) [4][5]. Industry Context - OrthoPediatrics operates within the Zacks Medical - Instruments industry, which includes other companies like OPKO Health, which has seen a decline of 1.5% over the past month [4].

Financial Performance - OrthoPediatrics Corp. announced preliminary unaudited net revenue for Q4 2025 and full year 2025, with specific figures to be confirmed post-audit[4] - The company provided management's projection for 2026 net revenue, indicating potential growth opportunities[4] - Free cash flow estimates for Q4 2025 and full year 2025 were also disclosed, subject to final audit results[6] - The company cautioned that actual results may differ materially from preliminary estimates due to various risks and uncertainties[6] - The financial information provided is preliminary and should not be relied upon without considering the associated risks[6] Compliance and Reporting - The press release is part of the company's ongoing compliance with SEC regulations, ensuring transparency in financial reporting[5] - The company has no obligation to publicly release updates on forward-looking statements unless required by law[6] Company Information - OrthoPediatrics Corp. is listed on the Nasdaq Global Market under the trading symbol "KIDS"[2] - The company is classified as an emerging growth company, which may affect its financial reporting standards[3] - The report was signed by Daniel J. Gerritzen, General Counsel and Secretary, on January 12, 2026[10]